Abstract: Objective To explore the effects of standard immunosuppressive therapy combined with magnesium isoglycyrrhizinate on the efficacy and immunoglobulins in patients with autoimmune hepatitis (AIH). Methods A total of 90 patients with AIH admitted to our hospital from March 2021 to March 2024 were selected. They were randomly divided into the immunosuppressive group (n=45) and the magnesium isoglycyrrhizinate group (n=45) by the envelope lottery method. The immunosuppressive group was treated with standard immunosuppressive therapy, and the magnesium isoglycyrrhizinate group was treated with magnesium isoglycyrrhizinate and standard immunosuppressive therapy. Compare the therapeutic effects, liver function [total bilirubin (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)], liver fibrosis indexes [hyaluronic acid (HA), laminin (LN), type III procollagen (PCⅢ)], immunoglobulin [IgA, IgG, IgM] and adverse reactions between the two groups. Results After treatment, the effective rate of the magnesium isoglycyrrhizinate group [93.3% (42/45)] was higher than that of the immunosuppressive group [77.8% (35/45)] (P<0.05); the levels of TBil (15.38 ± 1.41 μmol/L), ALT (56.35 ± 5.21 U/L), AST (48.44 ± 5.82 U/L), and ALP (69.44 ± 7.67 U/L) in the magnesium isoglycyrrhizinate group were lower than those in the immunosuppressive group (17.85 ± 1.78 μmol/L, 80.82 ± 8.03 U/L, 75.03 ± 7.71 U/L, 82.03 ± 9.32 U/L) (P<0.05); the levels of HA (136.43 ± 16.58 μg/L), LN (147.65 ± 16.65 μg/L), and PCⅢ (126.42 ± 13.77 μg/L) in the magnesium isoglycyrrhizinate group were all lower than those in the immunosuppressive group (174.41 ± 19.56, 188.67 ± 21.17, 168.85 ± 17.09 μg/L) (P<0.05); the levels of IgA (0.85 ± 0.29 g/L), IgM (14.73 ± 1.56 g/L), and IgG (1.42 ± 0.22 g/L) in the magnesium isoglycyrrhizinate group were all lower than those in the immunosuppressive group (1.09 ± 0.32, 16.10 ± 1.73, 1.57 ± 0.31 g/L) (P<0.05); there was no significant difference in the incidence of adverse reactions between the magnesium isoglycyrrhizinate group [8.9% (4/45)] and the immunosuppressive group [4.4% (2/45)] (P>0.05). Conclusion The combination of immunosuppressive therapy and magnesium isoglycyrrhizinate can significantly improve the treatment effect of patients with AIH and have a positive regulatory effect on their immunoglobulin levels.    

Key words: Standard immunosuppressive therapy, Magnesium isoglycyrrhizinate, Autoimmune hepatitis, Immunoglobulins